Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending May 2013. The report details a specific share repurchase transaction executed on May 14, 2013, pursuant to shareholder authority granted at the Annual General Meeting on May 1, 2013.
Key Financial Metrics
The filing does not provide data on revenue, profit, cash flow, margins, debt, or liquidity. It focuses exclusively on capital structure and share repurchase activity.
- Shares Purchased: 296,000 Ordinary Shares of 25 pence each.
- Price Range: Highest price paid was 1,693.5 pence per share; lowest price paid was 1,676.0 pence per share.
- Treasury Holdings (Settled): 498,431,327 shares (9.19% of total issued share capital).
- Treasury Holdings (Including Unsettled): 499,024,327 shares (10.13% of total voting rights).
- Shares in Issue (Excluding Treasury): 4,926,114,156 shares.
Material Changes
The filing reports an incremental increase in the Company's treasury share holdings following the purchase of 296,000 shares. No other material changes to financial position or operations are disclosed in this specific report.
Guidance, Outlook, and Risks
The filing contains no guidance, outlook, management commentary on future performance, or discussion of risks and contingencies. It is a compliance disclosure regarding share buybacks under the Financial Services Authority's Disclosure and Transparency Rules.
Investor Verification Points
- Verify the total number of shares held in Treasury (498,431,327 settled) against the Company's latest annual report.
- Confirm the total issued share capital to validate the 9.19% treasury ownership calculation.
- Check subsequent filings for the settlement status of the 593,000 shares purchased but not yet settled at the time of this report.
- Note that this filing does not contain financial performance metrics; refer to Form 20-F for comprehensive financial data.